دورية أكاديمية
SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy.
| العنوان: | SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy. |
|---|---|
| المؤلفون: | Lu L; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore., Chan CY; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore.; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore., Lim YY; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore., Than M; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore., Teo S; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore., Lau PYW; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore.; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore., Ng KH; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore.; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore., Yap HK; Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore.; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117549, Singapore. |
| المصدر: | Vaccines [Vaccines (Basel)] 2023 Dec 18; Vol. 11 (12). Date of Electronic Publication: 2023 Dec 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG |
| مستخلص: | Long-term humoral immunity is mediated by short-lived plasma cells (replenished by memory B cells) and long-lived plasma cells. Their relative contributions are uncertain for immunity to SARS-CoV-2, especially given the widespread use of novel mRNA vaccines. Yet, this has far-reaching implications in terms of the need for regular booster doses in the general population and perhaps even revaccination in patients receiving B cell-depleting therapy. We aimed to characterise anti-SARS-CoV-2 antibody titres in patients receiving Rituximab following previous SARS-CoV-2 vaccination. We recruited 10 fully vaccinated patients (age: 16.9 ± 2.52 years) with childhood-onset nephrotic syndrome, not in relapse, receiving Rituximab for their steroid/calcineurin-inhibitor sparing effect. Antibodies to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins were measured immediately prior to Rituximab and again ~6 months later, using the Roche Elecys ® Anti-SARS-CoV-2 (S) assay. All ten patients were positive for anti-S antibodies prior to Rituximab, with six patients (60%) having titres above the upper limit of detection (>12,500 U/mL). Following Rituximab therapy, there was a reduction in anti-S titres ( p = 0.043), but all patients remained positive for anti-S antibodies, with five patients (50%) continuing to have titres >12,500 U/mL. Six patients (60%) were positive for anti-N antibodies prior to Rituximab. Following Rituximab therapy, only three of these six patients remained positive for anti-N antibodies ( p = 0.036 compared to anti-S seroreversion). Humoral immunity to SARS-CoV-2 is likely to be mediated in part by long-lived plasma cells. |
| References: | N Engl J Med. 2021 Dec 9;385(24):e85. (PMID: 34706170) Emerg Infect Dis. 2022 Feb;28(2):338-346. (PMID: 34906291) Immunity. 2022 Jun 14;55(6):945-964. (PMID: 35637104) Immunity. 2022 May 10;55(5):749-780. (PMID: 35545027) N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326) Cells. 2023 Jun 23;12(13):. (PMID: 37443740) J Clin Rheumatol. 2022 Dec 1;28(8):381-389. (PMID: 35660717) Clin Rheumatol. 2023 Sep;42(9):2485-2490. (PMID: 37243801) Clin Transl Med. 2023 Jan;13(1):e1183. (PMID: 36658466) Lancet Infect Dis. 2023 Feb;23(2):150-152. (PMID: 36640796) Lancet Respir Med. 2021 Dec;9(12):1450-1466. (PMID: 34688434) Clin Infect Dis. 2021 Dec 16;73(12):2366-2368. (PMID: 33693643) Vaccines (Basel). 2021 Sep 28;9(10):. (PMID: 34696200) Pediatr Nephrol. 2023 Mar;38(3):877-919. (PMID: 36269406) Pediatr Nephrol. 2020 Aug;35(8):1529-1561. (PMID: 32382828) Curr Opin Immunol. 2018 Dec;55:81-88. (PMID: 30390507) Immunol Rev. 2022 Aug;309(1):40-63. (PMID: 35801537) Cell Res. 2021 Aug;31(8):827-828. (PMID: 34007056) J Med Virol. 2022 Jul;94(7):2939-2961. (PMID: 35229324) N Engl J Med. 2022 Sep 15;387(11):1011-1020. (PMID: 36044620) Kidney Int. 2020 Feb;97(2):393-401. (PMID: 31874801) N Engl J Med. 2022 Oct 6;387(14):1333-1336. (PMID: 36103621) Front Oncol. 2018 Jun 04;8:163. (PMID: 29915719) Lancet Microbe. 2023 Jul;4(7):e488. (PMID: 37086736) Nat Rev Immunol. 2022 Oct;22(10):591-592. (PMID: 35945353) Arthritis Rheum. 2003 Aug;48(8):2146-54. (PMID: 12905467) N Engl J Med. 2021 Jun 10;384(23):2259-2261. (PMID: 33822494) Vaccine. 2007 Jun 21;25(26):4931-9. (PMID: 17499406) Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. (PMID: 33400782) N Engl J Med. 2021 Oct 7;385(15):1393-1400. (PMID: 34525275) MMWR Morb Mortal Wkly Rep. 2023 Oct 20;72(42):1140-1146. (PMID: 37856366) N Engl J Med. 2007 Nov 8;357(19):1903-15. (PMID: 17989383) EBioMedicine. 2023 Sep;95:104735. (PMID: 37556944) Nat Rev Rheumatol. 2023 Feb;19(2):76-77. (PMID: 36517627) |
| معلومات مُعتمدة: | NMRC/CIRG/1447/2016 National Medical Research Council |
| فهرسة مساهمة: | Keywords: Rituximab; SARS-CoV-2; long-lived plasma cells; mRNA vaccines |
| تواريخ الأحداث: | Date Created: 20231223 Latest Revision: 20231225 |
| رمز التحديث: | 20231225 |
| مُعرف محوري في PubMed: | PMC10748262 |
| DOI: | 10.3390/vaccines11121864 |
| PMID: | 38140267 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2076-393X |
|---|---|
| DOI: | 10.3390/vaccines11121864 |